Table 1.
Characteristics of nAMD patients and controls.
| Category | nAMD | Control | P value | |||||
|---|---|---|---|---|---|---|---|---|
| N | Total | Typical | PCV | RAP | ||||
| Type 1 | Type 2 | |||||||
| 62 (100%) | 21 (34%) | 15 (24%) | 25 (40%) | 1 (2%) | 20 | Total nAMD vs. Control |
Among 4 groups | |
| Age (year) | 75# (46–94)† | 75 (55–88) | 77 (48–94) | 74 (46–94) | 81 | 72 (55–90) | 0.385 | 0.736 |
| Gender (M/F) | 41/21 | 16/5 | 9/6 | 15/10 | 1/0 | 8/12 | 0.070 | 0.134 |
Four groups comprised of type 1-, type 2- and PCV-nAMD groups and control group.
The comparison between total nAMD eyes and controls was examined by Mann-Whitney U test. The comparisons among 4 groups were examined by Kruskal-Wallis test. nAMD; neovascular age-related macular degeneration, PCV; polypoidal choroidal vasculopathy, RAP; retinal angiomatous proliferation, N; number, M; male, F; female, #; median, †; range.